US Broker Ratings

ATAI Life Sciences N.V. (ATAI) Stock Analysis: Unveiling a 109.53% Potential Upside in Biotech Innovation

ATAI Life Sciences N.V. (NASDAQ: ATAI), a prominent player in the biotechnology sector, is making waves with its innovative approach to mental health treatment. Based in..

Sana Biotechnology, Inc. (SANA) Stock Analysis: A Promising 66% Upside in the Cell Therapy Market

Sana Biotechnology, Inc. (NASDAQ: SANA) is generating buzz among investors with its robust potential for growth in the biotechnology sector, particularly in the field of engineered..

SIGA Technologies Inc. (SIGA) Stock Analysis: Uncovering the Growth Potential Behind a 271.90% Revenue Surge

SIGA Technologies Inc. (NASDAQ: SIGA), a prominent player in the healthcare sector, specializes in the manufacturing of specialty and generic drugs. With a current market capitalization..

Surmodics, Inc. (SRDX) Stock Analysis: Navigating a Challenging Yet Promising Healthcare Landscape

Surmodics, Inc. (NASDAQ: SRDX), a key player in the healthcare sector specializing in medical devices, presents a complex yet intriguing scenario for investors. With its headquarters..

Kamada Ltd. (KMDA) Stock Analysis: Exploring a Potential 105% Upside in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), a prominent player in the healthcare sector, is capturing investor attention with its robust pipeline of plasma-derived protein therapeutics and an impressive..

Auna SA (AUNA) Stock Analysis: Unpacking the 108.69% Potential Upside

Auna SA (AUNA), a Luxembourg-based healthcare giant, is garnering attention from investors with an enticing potential upside of 108.69%. Operating hospitals and clinics across Mexico, Peru,..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unveiling a Potential 95% Upside in the Biotech Sector

Bicara Therapeutics Inc. (NASDAQ: BCAX) is garnering significant attention from investors within the biotech sector, thanks to a remarkable potential upside of 95.28%. This clinical-stage biopharmaceutical..

Embecta Corp. (EMBC) Stock Analysis: Is a 22% Upside Within Reach?

Embecta Corp. (NASDAQ: EMBC) is garnering attention in the healthcare sector, particularly from investors seeking opportunities in medical instruments and supplies. With a market cap of..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: Navigating Challenges with a 1.84% Potential Upside

Sonida Senior Living, Inc. (SNDA), a key player in the healthcare sector, specifically in the medical care facilities industry, has been a focal point for investors..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Exploring a 32.55% Potential Upside in the Medical Devices Sector

Treace Medical Concepts, Inc. (NASDAQ: TMCI) operates in the healthcare sector, specifically within the medical devices industry, and is garnering attention due to its innovative solutions..

Prothena Corporation plc (PRTA) Stock Analysis: Exploring a 57% Potential Upside Amidst Biotech Sector Challenges

Prothena Corporation plc (NASDAQ: PRTA), a biotechnology firm headquartered in Dublin, Ireland, operates at the frontier of healthcare innovation, focusing on the development of novel therapies..

REGENXBIO Inc. (RGNX) Stock Analysis: Unpacking a 128% Potential Upside with Strong Buy Ratings

For investors with a keen eye on the biotechnology sector, REGENXBIO Inc. (NASDAQ: RGNX) presents an intriguing opportunity, underscored by a significant potential upside of 128.34%...

Arbutus Biopharma Corporation (ABUS) Stock Analysis: A High-Potential Biotech with 522% Revenue Growth

Arbutus Biopharma Corporation (NASDAQ: ABUS) presents a compelling opportunity for investors looking to tap into the high-growth potential of the biotechnology sector. With a market capitalization..

Replimune Group, Inc. (REPL) Stock Analysis: Eyeing a 3.66% Upside in the Biotech Sector

Replimune Group, Inc. (NASDAQ: REPL) has been catching the attention of investors with its promising oncolytic immunotherapies targeting cancer treatment. As a clinical-stage biotechnology company headquartered..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Potential 74% Upside

AbCellera Biologics Inc. (ABCL), a prominent player in the biotechnology sector, is making waves with its innovative approach to antibody-based medicine. Headquartered in Vancouver, Canada, the..

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: A Biotech Play with 180% Potential Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a burgeoning player in the biotechnology sector, presents an intriguing opportunity for investors with a risk appetite and a keen eye..

Dianthus Therapeutics, Inc. (DNTH) Rating Update: Analyst Consensus Suggests 84.15% Upside

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a promising player in the biotechnology sector, is attracting investor attention with a market capitalization of $1.34 billion. This clinical-stage company,..

Simulations Plus, Inc. (SLP) Stock Analysis: A Hidden Gem in Healthcare with 34% Upside Potential

Simulations Plus, Inc. (NASDAQ: SLP), a leader in the healthcare sector, is carving out a niche with its innovative drug discovery and development software solutions. With..

LifeMD, Inc. (LFMD) Stock Analysis: Unveiling a 121.98% Potential Upside in the Telehealth Revolution

LifeMD, Inc. (NASDAQ: LFMD) is stirring interest in the healthcare sector with its innovative approach to telehealth services. With a market capitalization of $275.02 million, LifeMD..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating Challenges with Strategic Collaborations in Molecular Diagnostics

Myriad Genetics, Inc. (NASDAQ: MYGN) stands at the forefront of the healthcare sector, specifically within the diagnostics and research industry. As a molecular diagnostic testing and..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds